Biosimilar CT-P13 matches infliximab in improving ankylosing spondylitis disease activity

World's first biosimilar monoclonal antibody provides cost-effective option

2014-06-11

(Press-News.org) New data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that the newly-approved infliximab biosimilar CT-P13 achieves statistically similar improvements in disease activity, disability and mobility in patients with Ankylosing Spondylitis (AS) compared to its original reference product infliximab (INX).1

CT-P13 is the world's first biosimilar monoclonal antibody to receive a positive opinion from an advanced and developed nations' regulatory body. According to Dr Won Park, Inha University Hospital, Korea, and lead investigator of the PLANETAS* study, "the challenge for biosimilars is to demonstrate similarity in therapeutic effectiveness, safety and immunogenicity to their reference product, not just biochemical and pharmacokinetic equivalence."

"By demonstrating comparable efficacy and safety, the results of our clinical trials should give physicians confidence in using CT-P13 as an alternative treatment option to INX in AS patients," Dr Park added. "This is good news for patients who may previously have had limited access to costly antibody biopharmaceuticals."

AS is a type of chronic arthritis affecting an estimated 1.4 million patients in Europe.2 In AS, inflammation in the joints and ligaments causes pain and stiffness in the neck, back and buttocks. The cause of AS is unknown, and there is no known cure, so the current aim of treatment is to reduce pain and stiffness and to keep the spine flexible.3

These new data captured clinical measures of disease activity via ASAS20/40 and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), disability via the Bath Ankylosing Spondylitis Functional Index (BASFI) and mobility via the Bath Ankylosing Spondylitis Metrology Index (BASMI). In addition, the Student's t test was used to compare mean change of three indices from baseline in both treatment groups.

At week 54, BASDAI improved significantly from baseline in both treatment groups (CT-P13: from 6.74 to 3.78 and INX: from 6.57 to 3.70) and this improvement was similar between groups (difference of means -0.29; CI of the difference -0.91 to 0.32). BASFI and BASMI were also similarly improved: BASFI (CT-P13: from 6.20 to 3.42 and INX: from 6.24 to 3.46) and BASMI (CT-P13: from 4.0 to 2.8 and INX: from 4.1 to 3.2). In addition, a 50% improvement of the baseline BASDAI (BASDAI50) was achieved in 44.3% for CT-P13 and 46.3% for INX at week 54; the BASDAI50 response rate was comparable between the two groups (p=0.7737).

A second objective of the study was to assess the effect of anti-drug antibody (ADA) on clinical outcomes. The use of biological agents can cause the production of ADA leading to reduced levels of treatment in the blood, impacting treatment response and/or increasing rates of infusion reaction. In the study, the presence of ADA was measured using electrochemiluminescent methodology and clinical responses in all treatment groups were examined in relation to the presence of ADA. Higher ASAS20/40 responses were seen in the ADA negative patients (72.7%/56.5%) compared with ADA positive patients (54.7%/37.7%) at week 54. The BASDAI and BASFI improved significantly in the ADA negative subgroup compared to the ADA positive subgroup (BASDAI: -3.13 vs. -2.30 and BASFI: -2.97 vs. -2.18), but no clear association with ADA was seen for BASMI. A greater clinical response was shown in the ADA negative subgroup in all three indices. However, the incidence of the ADA and their magnitude of impact on the clinical response or adverse event were similar between biosimilar CT-P13 and innovator infliximab.

CT-P13 has previously demonstrated pharmacokinetic (PK) equivalence to INX in the PLANETAS trial, a randomised double-blind, parallel group study of 250 patients with AS, and was recently approved by the European Medicines Agency.

INFORMATION:

Abstract Number: OP0157

NOTES TO EDITORS: For further information on this study, or to request an interview with the study lead, please contact us via: EULAR congress Press Office: Room 104, Palais des congrès de Paris Email: eularpressoffice@cohnwolfe.com Onsite tel: +44 (0) 7880 173209 Twitter: @EULAR_Press

About EULAR The European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with rheumatic diseases throughout Europe.

EULAR aims to promote, stimulate and support the research, prevention, and treatment of rheumatic diseases and the rehabilitation of those it affects. With 45 scientific member societies, 35 People with Arthritis and Rheumatism in Europe (PARE) organisations, 17 health professionals associations and 26 corporate members, EULAR highlights the importance of combating rheumatic diseases through both medical means and patient care. EULAR 2014 is set to be the biggest rheumatology event in Europe with almost 14,000 scientists, physicians, allied health professionals and related audiences in attendance from 130 countries. Over the course of the congress there will be 302 oral and 1,806 poster abstract presentations, 155 sessions, 725 lectures, 33 poster tours with 421 invited speakers. To find out more about the activities of EULAR, visit: http://www.eular.org

1Park W, Yoo DH, Szántó S, et al. Clinical response of disease activity, disability and mobility indices in relation to anti-drug antibody in the Planetas. EULAR 2014; Paris: Abstract OP0157
2 Morton L.. The Prevalence and burden of ankylosing spondylitis in Europe. University of Aberdeen.http://www.rheumatology.org.uk/includes/documents/cm_docs/2012/0/0930_oral_abstracts_spondyloarthropathies.pdf [Accessed 06/06/2014]
3 National Health Service. Ankylosing spondylitis. http://www.nhs.uk/conditions/ankylosing-spondylitis/pages/introduction.aspx. [Accessed 06/06/2014]

* Programme evaLuating the Autoimmune disease iNvEstigational drug cT-p13 in AS patients

ELSE PRESS RELEASES FROM THIS DATE:

New patient empowerment and educational initiatives unveiled at EULAR 2014

2014-06-11

Five different presentations at the European League Against Rheumatism Annual Congress (EULAR 2014) have introduced new patient empowerment and educational initiatives, which are predicted to bring significant benefits to the many thousands of patients worldwide who suffer from a rheumatic disease. These initiatives include: A new model of patient care involving self-monitoring and patient initiated follow-up1 An online learning resource to prepare patients and carers to actively engage in research, guideline development, advocacy and media activities2 A new patient ...

EULAR driving research and innovation in rheumatic and RMDs in Europe

2014-06-11

The European League Against Rheumatism (EULAR) has announced today at its Annual Congress major successes in driving the public agenda for addressing the escalating burden of RMDs in Europe. These advances include: Recognition for Rheumatic and Musculoskeletal Diseases (RMDs) from major European Commission research initiative, Horizon 2020 'FOREUM', Foundation for Research in Rheumatology, grants research funding for four osteoarthritis projects in its first year. "It is with great satisfaction that we have seen a progressive dedication of EU research funds for RMDs ...

Tendon stimulation the key to repair in 'tennis elbow'

2014-06-11

New data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that ultrasound-guided injections of growth factors-containing platelet-rich plasma (PRP) are no more effective in treating recently developed epicondylitis than injections of saline.1 Lead researcher, Patrick Le Goux of the Hôpitaux Universitaires Paris Ile-de-France Ouest, France, commented, "while PRP injections were shown to have no inherent benefit in the treatment of epicondylitis, what is exciting is that pain scores in both treatment groups decreased significantly ...

Higher disease activity scores in obese RA patients

2014-06-11

A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that obese patients with rheumatoid arthritis (RA) have higher DAS (disease activity) scores than non-obese patients, irrespective of their disease stage.1 With clinical remission as the ultimate therapeutic goal in RA,2 several studies have demonstrated that treatment to target – a treatment approach guided by its impact on reducing DAS scores – is more effective in lowering disease activity and, ultimately, reaching remission than usual care.3-7 Because obese patients ...

Newly discovered paddle prints show how ancient sea reptiles swam

2014-06-11

Trackways formed on an ancient seabed have shed new light on how nothosaurs, ancient marine reptiles that lived during the age of the dinosaurs, propelled themselves through water. The evidence is described by a team from Bristol and China in Nature Communications today. During the Mesozoic, 252-66 million years ago, the seas were ruled by a variety of marine reptiles. One of the earliest groups were the nothosaurs, voracious semi-aquatic hunters with elongate bodies and paddle-like limbs. They were the top predators of the Triassic coasts, some 245 million years ago. Their ...

Forest loss starves fish

2014-06-11

Debris from forests that washes into freshwater lakes supplements the diets of microscopic zooplankton and the fish that feed off them – creating larger and stronger fish, new research shows. The researchers warn that, as forests are eroded through human activities such as logging, the impacts will be felt in aquatic as well as terrestrial food chains. In fact, the study was conducted at a Canadian lake chosen because it had suffered ecological disaster during the mid-20th century: acid rain as a result of the local nickel smelting industry. Despite moves to reduce ...

Sports teams may lose out from having 'too much talent'

2014-06-11

As the FIFA World Cup kicks off and the NBA finals "heat" up, new research suggests that there is such a thing as having too much talent on a sports team. The research indicates that, after a certain point, the addition of more superstar talent to a team can actually be detrimental, resulting in poorer team performance. The findings are forthcoming in Psychological Science, a journal of the Association for Psychological Science. The research, led by INSEAD Professor Roderick Swaab, showed that the presence of too many individuals with top talent can undermine players' ...

Nearby satellite galaxies don't fit standard model

2014-06-11

Satellite dwarf galaxies at the edges of the Milky Way and neighboring Andromeda defy the accepted model of galaxy formation, and recent attempts to pigeon-hole them into the model are flawed, an international team of scientists reports. The mismatch raises questions about the accuracy of the standard model of cosmology, which is the widely accepted paradigm for the origin and evolution of the universe, the astrophysicists say. A preprint of the research paper, accepted for publication by the Monthly Notices of the Royal Astronomical Society, is online at http://arxiv.org/abs/1406.1799. The ...

Map of universe questioned; dwarf galaxies don't fit standard model

2014-06-11

Dwarf galaxies that orbit the Milky Way and the Andromeda galaxies defy the accepted model of galaxy formation, and recent attempts to wedge them into the model are flawed, reports an international team of astrophysicists. David Merritt, professor of astrophysics at Rochester Institute of Technology, co-authored "Co-orbiting satellite galaxy structures are still in conflict with the distribution of primordial dwarf galaxies," to be published in an upcoming issue of Monthly Notices of the Royal Astronomical Society. A pre-print of the paper is available online at http://arxiv.org/abs/1406.1799. The ...

Improvements in MRIs, other image-detection applications on the horizon

2014-06-11

LIVERMORE, Calif. — Researchers at Sandia National Laboratories, along with collaborators from Rice University and the Tokyo Institute of Technology, are developing new terahertz detectors based on carbon nanotubes that could lead to significant improvements in medical imaging, airport passenger screening, food inspection and other applications. A paper in Nano Letters journal, "Carbon Nanotube Terahertz Detector," debuted in the May 29 edition of the publication's "Just Accepted Manuscripts" section. The paper describes a technique that uses carbon nanotubes to detect ...

Biosimilar CT-P13 matches infliximab in improving ankylosing spondylitis disease activity

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: